Skip to main content

Peer Review reports

From: Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial

Original Submission
23 Oct 2020 Submitted Original manuscript
11 Mar 2021 Author responded Author comments - Quisette P Janssen
Resubmission - Version 2
11 Mar 2021 Submitted Manuscript version 2
14 Mar 2021 Editorially accepted
23 Mar 2021 Article published 10.1186/s12885-021-08031-z

You can find further information about peer review here.

Back to article page